AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12408922 — intervention group
Group type: COMPARATOR
Intervention: Formulation T (400 mg)
Number of subjects: 6
Study 10353452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management (ICM)
Number of subjects: 73
Study 10353452 — intervention group
Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 73
Study 7497762 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 micrograms/d)
Number of subjects: 30
Study 7497762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7497762 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 30
Study 1784501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration (0.25% with epinephrine 1:200,000)
Number of subjects: 14
Study 1784501 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infiltration (with epinephrine 1:200,000)
Number of subjects: 14
Study 1784501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration
Number of subjects: 14
Study 1784501 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infiltration
Number of subjects: 14
Study 6120713 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg)
Number of subjects: 6
Study 6120713 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg)
Number of subjects: 6
Study 6120713 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (20 mg)
Number of subjects: 6
Study 6120713 — intervention group
Group type: COMPARATOR
Intervention: Triprolidine (10 mg)
Number of subjects: 6
Study 31533762 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral design interventions
Number of subjects: 0
Study 31533762 — intervention group
Group type: COMPARATOR
Intervention: Standard vector control campaign methods
Number of subjects: 0
Study 27917488 — intervention group
Group type: EXPERIMENTAL
Intervention: Building a Healthy Me (BHM) nutrition intervention
Number of subjects: 414
Study 27917488 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 414
Study 26084668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg/day)
Number of subjects: 100
Study 26084668 — intervention group
Group type: COMPARATOR
Intervention: Voglibose (0.6 mg/day)
Number of subjects: 100
Study 24867891 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration (TA)
Number of subjects: 1498
Study 24867891 — intervention group
Group type: COMPARATOR
Intervention: Non-thrombus aspiration
Number of subjects: 1498
Study 21733185 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative use of the 3D-RX system
Number of subjects: 0
Study 21733185 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2D-fluoroscopy
Number of subjects: 0
Study 19204211 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 16996
Study 19204211 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids vs placebo
Number of subjects: 16996
Study 19204211 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids and long-acting β-agonists vs long-acting β-agonists
Number of subjects: 16996
Study 17673732 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic screening (invitation for electrocardiography)
Number of subjects: 14802
Study 17673732 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening (pulse taking and invitation for electrocardiography if the pulse was irregular)
Number of subjects: 14802
Study 17673732 — intervention group
Group type: COMPARATOR
Intervention: Control practices (no active screening)
Number of subjects: 14802
Study 14769141 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange plus conventional cancer chemotherapy
Number of subjects: 20
Study 14769141 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange plus continuous oral cyclophosphamide
Number of subjects: 20
Study 11465968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol therapy
Number of subjects: 112
Study 11465968 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 112
Study 9682351 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP‐OMP
Number of subjects: 102
Study 9682351 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC
Number of subjects: 102
Study 9682351 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP‐T
Number of subjects: 102
Study 7527328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 2 to 8 mg/day for 1 to 4 months
Number of subjects: 0
Study 7527328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 to 6 mg once daily
Number of subjects: 0
Study 7527328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0
Study 3205405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed magnetic stimuli applied over the scalp during tonic discharge of single hand muscle motor units (MUs)
Number of subjects: 0
Study 3205405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed magnetic stimuli applied over the scalp
Number of subjects: 0
Study 29792533 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience and Adjustment Intervention (RAI), delivered in seven 1-h sessions
Number of subjects: 160
Study 29792533 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience and Adjustment Intervention (RAI)
Number of subjects: 160
Study 29792533 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 160
Study 29163341 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial pulsed current stimulation (tPCS) alone
Number of subjects: 6
Study 29163341 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) combined with tPCS
Number of subjects: 6
Study 29163341 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) alone
Number of subjects: 6
Study 29163341 — intervention group
Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 6
Study 25765827 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberol(®)
Number of subjects: 175
Study 25765827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 23070789 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich juice (JUICE) 16 fl oz (230 mg flavonoids) ingested pre- and postworkout for 10 days
Number of subjects: 9
Study 23070789 — intervention group
Group type: COMPARATOR
Intervention: Nonathletic controls (n = 7)
Number of subjects: 9
Study 20462577 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS)
Number of subjects: 105
Study 20462577 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion sonohysterography (SIS)
Number of subjects: 105
Study 20462577 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic hysteroscopy (DH)
Number of subjects: 105
Study 18405345 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component motivational intervention based on the Theory of Planned Behaviour and volitional action planning
Number of subjects: 200
Study 18405345 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study 18405345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispensing medication packaged in the electronic medication-monitoring device
Number of subjects: 200
Study 18405345 — intervention group
Group type: COMPARATOR
Intervention: Conventional medication packaging
Number of subjects: 200
Study 17855795 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI followed by docetaxel/cisplatin (arm A)
Number of subjects: 169
Study 17855795 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC) monochemotherapy (arm B)
Number of subjects: 169
Study 12588788 — intervention group
Group type: EXPERIMENTAL
Intervention: GHEX (rHGH + exercise)
Number of subjects: 44
Study 12588788 — intervention group
Group type: EXPERIMENTAL
Intervention: SALEX (saline + exercise)
Number of subjects: 44
Study 12588788 — intervention group
Group type: COMPARATOR
Intervention: GH (rHGH without exercise)
Number of subjects: 44
Study 12588788 — intervention group
Group type: COMPARATOR
Intervention: Saline (without exercise)
Number of subjects: 44
Study 11139916 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-site RA pacing at AV interval of 100 ms
Number of subjects: 9
Study 11139916 — intervention group
Group type: COMPARATOR
Intervention: High RA pacing at AV interval of 200 ms
Number of subjects: 9
Study 11139916 — intervention group
Group type: COMPARATOR
Intervention: High RA pacing at AV interval of 50 ms
Number of subjects: 9
Study 9097297 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l-fenfluramine (60 mg p.o.)
Number of subjects: 20
Study 9097297 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH (100 micrograms i.v.)
Number of subjects: 20
Study 9097297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8331682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 22071
Study 8331682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 3080695 — intervention group
Group type: COMPARATOR
Intervention: Acute intravenous TRH (500 mg)
Number of subjects: 41
Study 3080695 — intervention group
Group type: COMPARATOR
Intervention: Chronic subcutaneous TRH (25 mg daily for 3 months)
Number of subjects: 41
Study 3080695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) in chronic studies
Number of subjects: 41
Study 3080695 — intervention group
Group type: COMPARATOR
Intervention: Placebo with norepinephrine in acute studies
Number of subjects: 41
Study 29212602 — intervention group
Group type: EXPERIMENTAL
Intervention: Control‐Cric™ System
Number of subjects: 70
Study 29212602 — intervention group
Group type: EXPERIMENTAL
Intervention: QuickTrach II™
Number of subjects: 70
Study 29212602 — intervention group
Group type: COMPARATOR
Intervention: Standard open surgical technique
Number of subjects: 70
Study 27741339 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% 5-Fluorouracil cream once daily for 4 weeks
Number of subjects: 841
Study 27741339 — intervention group
Group type: COMPARATOR
Intervention: 5% 5-Fluorouracil cream twice daily for 4 weeks
Number of subjects: 841
Study 27741339 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% 5-Fluorouracil cream once daily for 2 weeks
Number of subjects: 841
Study 25040898 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 139
Study 25040898 — intervention group
Group type: COMPARATOR
Intervention: Control education condition
Number of subjects: 139
Study 22722705 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic goal setting
Number of subjects: 29
Study 22722705 — intervention group
Group type: COMPARATOR
Intervention: Isolated goal setting
Number of subjects: 29
Study 19897255 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based daily muscle training for 12 months
Number of subjects: 63
Study 19897255 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 63
Study 18509347 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 9995
Study 15723739 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil omega-3 fatty acids (3 g/d)
Number of subjects: 43
Study 15723739 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil omega-3 fatty acids (3 g/d) and olive oil (9.6 mL)
Number of subjects: 43
Study 15723739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soy oil)
Number of subjects: 43
Study 12793996 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g aspirin treatment
Number of subjects: 0
Study 12793996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12545825 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + PA-MSHA vaccine
Number of subjects: 177
Study 12545825 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 177
Study 8806338 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 153
Study 8806338 — intervention group
Group type: COMPARATOR
Intervention: No drug therapy (Control)
Number of subjects: 153
Study 8806338 — intervention group
Group type: COMPARATOR
Intervention: Beta blockers and No drug therapy (Control)
Number of subjects: 153
Study 1463414 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.003% PhXA34 (1 microgram; n = 9)
Number of subjects: 29
Study 1463414 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% PhXA34 (3 micrograms; n = 10)
Number of subjects: 29
Study 1463414 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (n = 10)
Number of subjects: 29
Study 6698221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh semen
Number of subjects: 381
Study 6698221 — intervention group
Group type: COMPARATOR
Intervention: Cryopreserved semen
Number of subjects: 381
Study 31957963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (IABP)
Number of subjects: 100
Study 31957963 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 29722146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 4 hours before EST and then every 12 hours for 1 day, followed by high-dose oral esomeprazole for 10 days
Number of subjects: 125
Study 29722146 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 125
Study 29722146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole
Number of subjects: 125
Study 29722146 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 125
Study 26540314 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m²) and oxaliplatin (100 mg/m²) with panitumumab (6 mg/kg) for up to 12 cycles (arm A)
Number of subjects: 89
Study 26540314 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m²) and oxaliplatin (100 mg/m²) without panitumumab (arm B)
Number of subjects: 89
Study 26540314 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for intrahepatic cholangiocarcinoma treated with panitumumab
Number of subjects: 89
Study 26540314 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety profile of arm A (panitumumab)
Number of subjects: 89
Study 24213883 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation
Number of subjects: 16
Study 24213883 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training (HIT)
Number of subjects: 16
Study 22884381 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Training (IT) - cycling at 100% peak work rate for 30 seconds alternating with 30 seconds of rest
Number of subjects: 60
Study 22884381 — intervention group
Group type: COMPARATOR
Intervention: Continuous Training (CT) - cycling at 60% of peak work rate
Number of subjects: 60
Study 20386070 — intervention group
Group type: EXPERIMENTAL
Intervention: bosentan (125 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily)
Number of subjects: 12
Study 20386070 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir (400/100 mg twice daily)
Number of subjects: 12
Study 18525036 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling program that encouraged abrupt weaning at 4 months
Number of subjects: 958
Study 18525036 — intervention group
Group type: COMPARATOR
Intervention: Standard practice encouraging continued breast-feeding for as long as the women chose
Number of subjects: 958
Study 15712076 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5% albumin
Number of subjects: 150
Study 12088162 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 60
Study 12088162 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 60
Study 10206447 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1.5 to 2.25 g/d) for 6.1+/‐5.1 months
Number of subjects: 43
Study 10206447 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1.5 to 2.25 g/d)
Number of subjects: 43
Study 8580383 — intervention group
Group type: EXPERIMENTAL
Intervention: RFLP‐A polymorphism of the interleukin 1 receptor type I gene (IL1RI)
Number of subjects: 0
Study 8580383 — intervention group
Group type: COMPARATOR
Intervention: RFLP‐B polymorphism of the interleukin 1 receptor type I gene (IL1RI)
Number of subjects: 0
Study 2611735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement counselling
Number of subjects: 30
Study 613552 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral treatment with triamcinolone acetonide (Kenacort A) - 80 mg for the 1st and 2nd injections, 40 mg for the 3rd to 7th injections at two-week intervals
Number of subjects: 40
Study 613552 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral treatment with triamcinolone acetonide (Kenacort A)
Number of subjects: 40
Study 613552 — intervention group
Group type: COMPARATOR
Intervention: Oral treatment with prednisolone - initial dosage of 30 mg followed by reduced dosage for 6 months
Number of subjects: 40
Study 31749182 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous graft
Number of subjects: 29
Study 31749182 — intervention group
Group type: COMPARATOR
Intervention: Synthetic graft
Number of subjects: 29
Study 28822974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (3.5 μg/kg + 5 μg/kg/hour CRI)
Number of subjects: 6
Study 28822974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (3.5 μg/kg + 3.5 μg/kg/hour CRI) and Butorphanol (20 μg/kg + 24 μg/kg/hour CRI)
Number of subjects: 6
Study 24791752 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GSH 1,000 mg/day
Number of subjects: 54
Study 24791752 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GSH 250 mg/day
Number of subjects: 54
Study 24791752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23499546 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod (16 weeks, three times a week)
Number of subjects: 246
Study 23499546 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluorouracil (16 weeks, twice a week)
Number of subjects: 246
Study 23499546 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery (monthly for 4 months)
Number of subjects: 246
Study 23499546 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod
Number of subjects: 246
Study 23499546 — intervention group
Group type: COMPARATOR
Intervention: Topical fluorouracil
Number of subjects: 246
Study 23499546 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 246
Study 21188380 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with capecitabine and mitomycin C
Number of subjects: 49
Study 19081416 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8194
Study 19081416 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8194
Study 17243139 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 83
Study 17243139 — intervention group
Group type: COMPARATOR
Intervention: LPS stimulation
Number of subjects: 83
Study 10879716 — intervention group
Group type: EXPERIMENTAL
Intervention: Open low-field MR system (0.2 T)
Number of subjects: 38
Study 10879716 — intervention group
Group type: COMPARATOR
Intervention: Standard high-field MR system (1.5 T)
Number of subjects: 38
Study 8878306 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashbackers during flashbacks
Number of subjects: 56
Study 8878306 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with persistent MAP psychosis
Number of subjects: 56
Study 8878306 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-flashbackers
Number of subjects: 56
Study 8878306 — intervention group
Group type: COMPARATOR
Intervention: Control group (61 physically healthy prisoners)
Number of subjects: 56
Study 2049239 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorocresol and chlorbutol
Number of subjects: 8
Study 2049239 — intervention group
Group type: COMPARATOR
Intervention: Saline (as placebo)
Number of subjects: 8
Study 6659894 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric contact lens designs
Number of subjects: 0
Study 6659894 — intervention group
Group type: COMPARATOR
Intervention: Conventional spherical design
Number of subjects: 0
Study 30614066 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care group (quarterly check-ups by general practitioners)
Number of subjects: 140
Study 30614066 — intervention group
Group type: COMPARATOR
Intervention: Control group (mono-sectorial management in a specialized outpatient clinic, quarterly check-ups by endocrinologists)
Number of subjects: 140
Study 29161523 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 202
Study 29161523 — intervention group
Group type: COMPARATOR
Intervention: Nonpropranolol Control
Number of subjects: 202
Study 26581884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 95
Study 26581884 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban
Number of subjects: 95
Study 26581884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor and Tirofiban
Number of subjects: 95
Study 24655569 — intervention group
Group type: EXPERIMENTAL
Intervention: VR of a natural environment
Number of subjects: 0
Study 24655569 — intervention group
Group type: EXPERIMENTAL
Intervention: VR of an urban environment
Number of subjects: 0
Study 24655569 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 22151078 — intervention group
Group type: EXPERIMENTAL
Intervention: Live donor (LD) liver transplantation
Number of subjects: 295
Study 22151078 — intervention group
Group type: COMPARATOR
Intervention: Deceased donor (DD) liver transplantation
Number of subjects: 295
Study 19933409 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) testing
Number of subjects: 0
Study 19933409 — intervention group
Group type: COMPARATOR
Intervention: Non-BNP group (control)
Number of subjects: 0
Study 18034397 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination therapy of dexamethasone and gentamicin
Number of subjects: 0
Study 18034397 — intervention group
Group type: COMPARATOR
Intervention: Separate application of dexamethasone and gentamicin sulfate
Number of subjects: 0
Study 16182897 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits (n=175)
Number of subjects: 350
Study 16182897 — intervention group
Group type: COMPARATOR
Intervention: No home visits (n=175)
Number of subjects: 350